{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:55:27Z","timestamp":1793757327212,"version":"4.6.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-14064-2","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T14:28:29Z","timestamp":1754490509000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world pharmacovigilance assessment of hepatotoxicity risk with HER2-Targeted drugs using FAERS database analysis"],"prefix":"10.1038","volume":"15","author":[{"given":"Junli","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyu","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"14064_CR1","doi-asserted-by":"crossref","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74 (3), 229\u2013263 (2024). 21834.","DOI":"10.3322\/caac.21834"},{"key":"14064_CR2","doi-asserted-by":"publisher","first-page":"116101","DOI":"10.1016\/j.bcp.2024.116101","volume":"223","author":"N Chen","year":"2024","unstructured":"Chen, N. et al. HER2 targeted therapy in colorectal cancer: Current landscape and future directions. Biochem. Pharmacol. 223, 116101. https:\/\/doi.org\/10.1016\/j.bcp.2024.116101 (2024).","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"14064_CR3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","volume":"17","author":"DY Oh","year":"2020","unstructured":"Oh, D. Y. & Bang, Y. J. HER2-targeted therapies\u2014a role beyond breast cancer. Nat. Rev. Clin. Oncol. 17 (1), 33\u201348. https:\/\/doi.org\/10.1038\/s41571-019-0268-3 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"14064_CR4","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s10555-016-9649-6","volume":"35","author":"JL Hsu","year":"2016","unstructured":"Hsu, J. L. & Hung, M. C. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metastasis Rev. 35 (4), 575\u2013588. https:\/\/doi.org\/10.1007\/s10555-016-9649-6 (2016).","journal-title":"Cancer Metastasis Rev."},{"key":"14064_CR5","doi-asserted-by":"publisher","unstructured":"Pous, A. et al. HER2-Positive gastric cancer: The role of immunotherapy and novel therapeutic strategies. Int. J. Mol. Sci. 24 (14). https:\/\/doi.org\/10.3390\/ijms241411403 (2023).","DOI":"10.3390\/ijms241411403"},{"issue":"2","key":"14064_CR6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga, J. et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366 (2), 109\u2013119 (2012). https:\/\/doi.org\/10.1056\/NEJMoa1113216.","journal-title":"N Engl. J. Med."},{"key":"14064_CR7","doi-asserted-by":"publisher","unstructured":"Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 376(9742), 687\u201397 (2010). https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X.","DOI":"10.1016\/S0140-6736(10)61121-X"},{"issue":"4","key":"14064_CR8","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","volume":"20","author":"F Meric-Bernstam","year":"2019","unstructured":"Meric-Bernstam, F. et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): An updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 20 (4), 518\u2013530 (2019).","journal-title":"Lancet Oncol."},{"issue":"17","key":"14064_CR9","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1200\/JCO.19.02318","volume":"38","author":"S Modi","year":"2020","unstructured":"Modi, S. et al. Antitumor activity and safety of trastuzumab Deruxtecan in patients with HER2-Low-Expressing advanced breast cancer: Results from a phase Ib study. J. Clin. Oncol. 38 (17), 1887\u20131896 (2020).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"14064_CR10","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s12072-023-10633-7","volume":"18","author":"Y Mao","year":"2024","unstructured":"Mao, Y. et al. Chinese guideline for the diagnosis and treatment of drug-induced liver injury: An update. Hepatol. Int. 18 (2), 384\u2013419. https:\/\/doi.org\/10.1007\/s12072-023-10633-7 (2024).","journal-title":"Hepatol. Int."},{"issue":"10","key":"14064_CR11","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/apt.18271","volume":"60","author":"A Fettiplace","year":"2024","unstructured":"Fettiplace, A. et al. Review article: recommendations for detection, assessment and management of suspected drug-induced liver injury during clinical trials in oncology patients. Aliment. Pharmacol. Ther. 60 (10), 1293\u20131307 (2024). https:\/\/doi.org\/10.1111\/apt.18271","journal-title":"Aliment. Pharmacol. Ther."},{"key":"14064_CR12","doi-asserted-by":"publisher","unstructured":"Barbieri, M. A. et al. Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database. Drugs Real World Outcomes. ;9(1):91\u2013107. (2022). Santoro, Paola Maria Cutroneo, Tindara Franchina, and Edoardo Spina have no conflicts of interest that are relevant to the content of this article. The research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. https:\/\/doi.org\/10.1007\/s40801-021-00278-z","DOI":"10.1007\/s40801-021-00278-z"},{"key":"14064_CR13","doi-asserted-by":"publisher","unstructured":"Ma, P. et al. High risks adverse events associated with trastuzumab emtansine and trastuzumab Deruxtecan for the treatment of HER2-positive\/mutated malignancies: A pharmacovigilance study based on the FAERS database. Expert Opin. Drug Saf. 2023 22(8), 685\u2013696. https:\/\/doi.org\/10.1080\/14740338.2023.2204228.","DOI":"10.1080\/14740338.2023.2204228"},{"issue":"8","key":"14064_CR14","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1080\/14740338.2023.2277801","volume":"23","author":"C Sun","year":"2024","unstructured":"Sun, C. et al. A pharmacovigilance study on drug-induced liver injury associated with antibody-drug conjugates (ADCs) based on the food and drug administration adverse event reporting system. Expert Opin. Drug Saf. 23 (8), 1049\u20131060 (2024).","journal-title":"Expert Opin. Drug Saf."},{"issue":"9","key":"14064_CR15","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1002\/ijc.34848","volume":"154","author":"H Chen","year":"2024","unstructured":"Chen, H., Yang, G. & Ma, J. Ocular toxicity associated with anti-HER2 agents in breast cancer: A pharmacovigilance analysis using the FAERS database. Int. J. Cancer. 154 (9), 1616\u20131625 (2024). .34848. PubMed PMID: 38216995.","journal-title":"Int. J. Cancer"},{"key":"14064_CR16","doi-asserted-by":"publisher","unstructured":"Fusaroli, M., Salvo, F., Begaud, B. & Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV). The REporting of A : Explanation and Elaboration. Drug Saf. 47(6):585\u2013599. Mahaux and Andrew Bate are full-time employees at GSK and own GSK restricted shares. Manfred Hauben was a full-time employee at Pfizer when the Delphi was conducted and owns stock\/stock options in pharmaceutical companies that may manufacture\/market drugs mentioned in this paper. Michele Fusaroli, Francesco Salvo, Bernard Begaud, Thamir M. AlShammari, Vera Battini, Andreas Brueckner, Carla Carnovale, Salvatore Crisafulli, Paola Maria Cutroneo, Charles Dolladille, Milou-Daniel Drici, Jean-Luc Faillie, Adam Goldman, Maria Teresa Herdeiro, Francois Montastruc, Yoshihiro Noguchi, G. Niklas Noren, Roberta Noseda, Igho J. Onakpoya, Antoine Pariente, Elisabetta Poluzzi, Myriam Salem, Daniele Sartori, Nhung T.H. Trinh, Marco Tuccori, Florence van Hunsel, Eugene van Puijenbroek, Emanuel Raschi, and Charles Khouri declare no conflicts of interest in relation to this research. (2024). https:\/\/doi.org\/10.1007\/s40264-024-01423-7","DOI":"10.1007\/s40264-024-01423-7"},{"key":"14064_CR17","doi-asserted-by":"publisher","unstructured":"Fusaroli, M. et al. The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement. Drug Saf. ;47(6):575\u2013584. (2024). Mahaux and Andrew Bate are full-time employees at GSK and own GSK restricted shares. Manfred Hauben was a full-time employee at Pfizer when the Delphi was conducted and owns stock\/stock options in pharmaceutical companies that may manufacture\/market drugs mentioned in this paper. The remaining authors declare no conflict of interest specific for this research. https:\/\/doi.org\/10.1007\/s40264-024-01421-9","DOI":"10.1007\/s40264-024-01421-9"},{"key":"14064_CR18","doi-asserted-by":"publisher","unstructured":"Russo, G. et al. Renal disorders with oral tyrosine kinase inhibitors in metastatic colorectal cancer: An analysis from the FDA adverse event reporting system database. Biomedicines 11 (8). https:\/\/doi.org\/10.3390\/biomedicines11082311 (2023).","DOI":"10.3390\/biomedicines11082311"},{"issue":"5","key":"14064_CR19","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00228-025-03824-8","volume":"81","author":"MA Barbieri","year":"2025","unstructured":"Barbieri, M. A. et al. Unveiling cardiovascular and respiratory toxicities with monoclonal antibodies in multiple myeloma: Disproportionality analysis from the FDA adverse event reporting system. Eur. J. Clin. Pharmacol. 81 (5), 755\u2013770. https:\/\/doi.org\/10.1007\/s00228-025-03824-8 (2025).","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"3","key":"14064_CR20","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.yrtph.2015.05.004","volume":"72","author":"A Suzuki","year":"2015","unstructured":"Suzuki, A. et al. Comedications alter drug-induced liver injury reporting frequency: data mining in the WHO vigibase. Regul. Toxicol. Pharmacol. 72 (3), 481\u2013490. https:\/\/doi.org\/10.1016\/j.yrtph.2015.05.004 (2015).","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"3","key":"14064_CR21","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s11096-022-01397-5","volume":"44","author":"C Wei","year":"2022","unstructured":"Wei, C. et al. A pharmacovigilance study of the association between tetracyclines and hepatotoxicity based on food and drug administration adverse event reporting system data. Int. J. Clin. Pharm. 44 (3), 709\u2013716. https:\/\/doi.org\/10.1007\/s11096-022-01397-5 (2022).","journal-title":"Int. J. Clin. Pharm."},{"issue":"11","key":"14064_CR22","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1248\/bpb.b19-00156","volume":"42","author":"G Ando","year":"2019","unstructured":"Ando, G. et al. Evaluation of the expression time of Ganciclovir-Induced adverse events using JADER and FAERS. Biol. Pharm. Bull. 42 (11), 1799\u20131804. https:\/\/doi.org\/10.1248\/bpb.b19-00156 (2019).","journal-title":"Biol. Pharm. Bull."},{"issue":"8","key":"14064_CR23","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman, K. J., Lanes, S. & Sacks, S. T. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 13 (8), 519\u2013523 (2004).","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"14064_CR24","doi-asserted-by":"publisher","unstructured":"Cutroneo, P. M. S. D. et al. Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems. Front. Drug Saf. 2024;Regul 3, 1323057. https:\/\/doi.org\/10.3389\/fdsfr.2023.1323057","DOI":"10.3389\/fdsfr.2023.1323057"},{"issue":"8","key":"14064_CR25","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1080\/14740338.2024.2368817","volume":"23","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli, M. et al. The evolving role of disproportionality analysis in pharmacovigilance. Expert Opin. Drug Saf. 23 (8), 981\u2013994 (2024).","journal-title":"Expert Opin. Drug Saf."},{"issue":"2","key":"14064_CR26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/sj.clpt.6100258","volume":"82","author":"JS Almenoff","year":"2007","unstructured":"Almenoff, J. S. et al. Novel statistical tools for monitoring the safety of marketed drugs. Clin. Pharmacol. Ther. 82 (2), 157\u2013166. https:\/\/doi.org\/10.1038\/sj.clpt.6100258 (2007).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"14064_CR27","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s10549-021-06145-3","volume":"187","author":"S Kuemmel","year":"2021","unstructured":"Kuemmel, S. et al. Subcutaneous trastuzumab with Pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of metapher, a phase IIIb single-arm safety study. Breast Cancer Res. Treat. 187 (2), 467\u2013476. https:\/\/doi.org\/10.1007\/s10549-021-06145-3 (2021).","journal-title":"Breast Cancer Res. Treat."},{"key":"14064_CR28","doi-asserted-by":"publisher","unstructured":"Garcia-Alvarez, A., Papakonstantinou, A. & Oliveira, M. Brain metastases in HER2-Positive breast cancer: Current and novel treatment strategies. Cancers (Basel). 13 (12). https:\/\/doi.org\/10.3390\/cancers13122927 (2021).","DOI":"10.3390\/cancers13122927"},{"issue":"3","key":"14064_CR29","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1056\/NEJMra1816149","volume":"381","author":"JH Hoofnagle","year":"2019","unstructured":"Hoofnagle, J. H. & Bjornsson, E. S. Drug-Induced liver Injury\u2014Types and phenotypes. N. Engl. J. Med. 381 (3), 264\u2013273 (2019). https:\/\/doi.org\/10.1056\/NEJMra1816149.","journal-title":"N Engl. J. Med."},{"issue":"5","key":"14064_CR30","doi-asserted-by":"publisher","first-page":"878","DOI":"10.14309\/ajg.0000000000001259","volume":"116","author":"NP Chalasani","year":"2021","unstructured":"Chalasani, N. P. et al. ACG clinical guideline: Diagnosis and management of idiosyncratic Drug-Induced liver injury. Am. J. Gastroenterol. 116 (5), 878\u2013898 (2021). https:\/\/doi.org\/10.14309\/ajg.0000000000001259","journal-title":"Am. J. Gastroenterol."},{"key":"14064_CR31","doi-asserted-by":"publisher","first-page":"101795","DOI":"10.1016\/j.eclinm.2022.101795","volume":"55","author":"Z Fu","year":"2023","unstructured":"Fu, Z. et al. Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: A systematic review and meta-analysis. EClinicalMedicine 55, 101795. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101795 (2023).","journal-title":"EClinicalMedicine"},{"key":"14064_CR32","doi-asserted-by":"publisher","first-page":"204209862413046","DOI":"10.1177\/20420986241304680","volume":"15","author":"P Yang","year":"2024","unstructured":"Yang, P. et al. Incidence of antibody-drug conjugate-related hepatotoxicity in breast cancer: A systematic review and meta-analysis. Ther. Adv. Drug Saf. 15, 20420986241304680 (2024). https:\/\/doi.org\/10.1177\/20420986241304680.","journal-title":"Ther. Adv. Drug Saf."},{"key":"14064_CR33","doi-asserted-by":"publisher","unstructured":"Tarantino, P. et al. Optimizing the safety of antibody-drug conjugates for patients with solid tumours. Nat. Rev. Clin. Oncol.. 20(8), 558\u2013576. (2023). https:\/\/doi.org\/10.1038\/s41571-023-00783-w.","DOI":"10.1038\/s41571-023-00783-w"},{"issue":"8","key":"14064_CR34","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet, C. et al. Antibody-drug conjugates come of age in oncology. Nat. Rev. Drug Discov. 22 (8), 641\u2013661. https:\/\/doi.org\/10.1038\/s41573-023-00709-2 (2023).","journal-title":"Nat. Rev. Drug Discov"},{"issue":"3","key":"14064_CR35","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1158\/1535-7163.MCT-15-0580","volume":"15","author":"H Yan","year":"2016","unstructured":"Yan, H. et al. Ado-Trastuzumab emtansine targets hepatocytes via human epidermal growth factor receptor 2 to induce hepatotoxicity. Mol. Cancer Ther. 15 (3), 480\u2013490. https:\/\/doi.org\/10.1158\/1535-7163.MCT-15-0580 (2016).","journal-title":"Mol. Cancer Ther."},{"issue":"13","key":"14064_CR36","first-page":"3384","volume":"60","author":"LN Klapper","year":"2000","unstructured":"Klapper, L. N. et al. Tumor-inhibitory antibodies to HER-2\/ErbB-2 May act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res. 60 (13), 3384\u20133388 (2000).","journal-title":"Cancer Res."},{"issue":"9","key":"14064_CR37","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1111\/j.1349-7006.2007.00553.x","volume":"98","author":"K Sakai","year":"2007","unstructured":"Sakai, K. et al. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway. Cancer Sci. 98 (9), 1498\u20131503. https:\/\/doi.org\/10.1111\/j.1349-7006.2007.00553.x (2007).","journal-title":"Cancer Sci."},{"issue":"19","key":"14064_CR38","first-page":"5485","volume":"62","author":"N Mendoza","year":"2002","unstructured":"Mendoza, N. et al. Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer. Cancer Res. 62 (19), 5485\u20135488 (2002).","journal-title":"Cancer Res."},{"issue":"2","key":"14064_CR39","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/toxsci\/65.2.166","volume":"65","author":"H Jaeschke","year":"2002","unstructured":"Jaeschke, H. et al. Mechanisms of hepatotoxicity. Toxicol. Sci. 65 (2), 166\u2013176. https:\/\/doi.org\/10.1093\/toxsci\/65.2.166 (2002).","journal-title":"Toxicol. Sci."},{"issue":"1","key":"14064_CR40","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cld.2016.08","volume":"21","author":"AI Shehu","year":"2017","unstructured":"Shehu, A. I., Ma, X. & Venkataramanan, R. Mechanisms of Drug-Induced hepatotoxicity. Clin. Liver Dis. 21 (1), 35\u201354. https:\/\/doi.org\/10.1016\/j.cld.2016.08 (2017).","journal-title":"Clin. Liver Dis."},{"issue":"1","key":"14064_CR41","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40360-023-00702-w","volume":"24","author":"SP Zou","year":"2023","unstructured":"Zou, S. P. et al. A disproportionality analysis of adverse events associated to Pertuzumab in the FDA adverse event reporting system (FAERS). BMC Pharmacol. Toxicol. 24 (1), 62. https:\/\/doi.org\/10.1186\/s40360-023-00702-w (2023).","journal-title":"BMC Pharmacol. Toxicol."},{"issue":"6","key":"14064_CR42","first-page":"354","volume":"98","author":"J Phillips","year":"2018","unstructured":"Phillips, J. & Henderson, A. C. Hemolytic anemia: Evaluation and differential diagnosis. Am. Fam. Phys. 98 (6), 354\u2013361 (2018).","journal-title":"Am. Fam Physician"},{"issue":"6","key":"14064_CR43","doi-asserted-by":"publisher","first-page":"G668","DOI":"10.1152\/ajpgi.00026.2018","volume":"314","author":"L Weaver","year":"2018","unstructured":"Weaver, L. et al. Biliverdin reductase and bilirubin in hepatic disease. Am. J. Physiol. Gastrointest. Liver Physiol. 314 (6), G668\u2013G676. https:\/\/doi.org\/10.1152\/ajpgi.00026.2018 (2018).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"1","key":"14064_CR44","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/toxsci\/kfad099","volume":"197","author":"S Chen","year":"2023","unstructured":"Chen, S. et al. The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib. Toxicol. Sci. 197 (1), 69\u201378. https:\/\/doi.org\/10.1093\/toxsci\/kfad099 (2023).","journal-title":"Toxicol. Sci."},{"key":"14064_CR45","doi-asserted-by":"publisher","unstructured":"Vigano, M. et al. Hepatotoxicity of small molecule protein kinase inhibitors for cancer. Cancers (Basel). 15 (6). https:\/\/doi.org\/10.3390\/cancers15061766 (2023).","DOI":"10.3390\/cancers15061766"},{"key":"14064_CR46","doi-asserted-by":"publisher","first-page":"108040","DOI":"10.1016\/j.compbiomed.2024.108040","volume":"170","author":"M Tang","year":"2024","unstructured":"Tang, M., Wu, Z. E. & Li, F. Integrating network Pharmacology and drug side-effect data to explore mechanism of liver injury-induced by tyrosine kinase inhibitors. Comput. Biol. Med. 170, 108040 (2024).","journal-title":"Comput. Biol. Med."},{"key":"14064_CR47","doi-asserted-by":"publisher","unstructured":"Gharwan, H. & Groninger, H. Kinase inhibitors and monoclonal antibodies in oncology: Clinical implications. Nat. Rev. Clin. Oncol. 13(4), 209\u201327. (2016). https:\/\/doi.org\/10.1038\/nrclinonc.2015.213.","DOI":"10.1038\/nrclinonc.2015.213"},{"key":"14064_CR48","doi-asserted-by":"publisher","first-page":"110602","DOI":"10.1016\/j.intimp.2023.110602","volume":"122","author":"X Wu","year":"2023","unstructured":"Wu, X. et al. Emerging insights into mechanisms of trastuzumab resistance in HER2-positive cancers. Int. Immunopharmacol. 122, 110602. https:\/\/doi.org\/10.1016\/j.intimp.2023.110602 (2023).","journal-title":"Int. Immunopharmacol."},{"key":"14064_CR49","doi-asserted-by":"publisher","first-page":"1030832","DOI":"10.3389\/fphar.2023.1030832","volume":"14","author":"K Onda","year":"2023","unstructured":"Onda, K., Honma, T. & Masuyama, K. Methotrexate-related adverse events and impact of concomitant treatment with folic acid and tumor necrosis factor-alpha inhibitors: An assessment using the FDA adverse event reporting system. Front. Pharmacol. 14, 1030832 (2023).","journal-title":"Front. Pharmacol."},{"issue":"1","key":"14064_CR50","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40360-024-00738-6","volume":"25","author":"T Honma","year":"2024","unstructured":"Honma, T., Onda, K. & Masuyama, K. Drug-drug interaction assessment based on a large-scale spontaneous reporting system for hepato- and renal-toxicity, and thrombocytopenia with concomitant low-dose methotrexate and analgesics use. BMC Pharmacol. Toxicol. 25 (1), 13. https:\/\/doi.org\/10.1186\/s40360-024-00738-6 (2024).","journal-title":"BMC Pharmacol. Toxicol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14064-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14064-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14064-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T21:59:12Z","timestamp":1757368752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14064-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14064"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-14064-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"13 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28790"}}